source
- US-China biotech rivalry sparks calls for deeper discussion, says editorThe editor notes that the ongoing debate over the competitive relationship between U.S. and Chinese biotechnology sectors has been unfolding over recent months. While many knowledgeable voices are…
- Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves aheadAurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…